--- canonical_name: Stephania tetrandra alternate_names: Han Fang Ji, Fang Ji, Fen Fang Ji, Stephaniae Tetrandrae Radix, Tetrandra Root, Stephania Root canonical_topic: Stephania tetrandra for Health & Longevity short_topic_lc: stephania_tetrandra creation_date: 2026-0825-1205 creator_ai_fullname: Opus 5 ep_keywords: Bisbenzylisoquinoline Alkaloids, Alkaloids, Traditional Chinese Medicine --- # Stephania tetrandra for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Han Fang Ji, Fang Ji, Fen Fang Ji, Stephaniae Tetrandrae Radix, Tetrandra Root, Stephania Root ## Motivation *Stephania tetrandra* is a climbing vine from southern China whose thick root, called han fang ji, has been used for centuries to relieve swelling, joint pain and difficult urination. Its most studied ingredient is tetrandrine, a plant compound that slows the entry of calcium into cells and damps down inflammation. The root has drawn attention outside Asia because that same compound keeps reappearing in modern laboratory screens for very different diseases. In China the purified compound has been a licensed treatment for dust-related lung scarring for decades, which makes it one of very few plant medicines to reach that standing anywhere. The root also carries an unusual burden. A different and unrelated plant, sold under a confusingly similar Chinese name, caused an outbreak of kidney failure and urinary tract cancer in Europe in the 1990s, and the two roots are still mixed up in trade today. This review examines what human and laboratory work actually shows about the root and its main compound: where effects have been measured in people, where the case rests on animal work alone, and how the hazards, including the mix-up problem, sit alongside the reported gains. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading A short set of high-level sources that orient a reader to the root, its principal compound, and the safety controversy attached to the name it is sold under. * [Tetrandrine--A molecule of wide bioactivity](https://pubmed.ncbi.nlm.nih.gov/26899361/) - Bhagya & Chandrashekar, 2016 The best single orientation to the root's principal compound: its distribution, extraction, calcium-channel and drug-efflux actions, and the conditions in which it has actually been tested in people. * [Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)](https://pubmed.ncbi.nlm.nih.gov/10841870/) - Nortier et al., 2000 The primary report behind the substitution hazard: urothelial carcinoma (cancer of the urinary tract lining) in Belgian slimming-clinic patients who received the wrong "fang ji" species, rising with cumulative dose. * [Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment](https://pubmed.ncbi.nlm.nih.gov/25722412/) - Sakurai et al., 2015 The paper that brought tetrandrine to Western attention, identifying the endosomal two-pore channel as its target and reporting a survival benefit in infected mice. * [Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action](https://pubmed.ncbi.nlm.nih.gov/12466042/) - Kwan & Achike, 2002 A detailed treatment of the blood-pressure and cardiac effects, covering calcium-entry blockade, adrenal steroid output and vascular remodelling — the basis for every cardiovascular claim made for this root. * [Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy](https://pubmed.ncbi.nlm.nih.gov/27027348/) - Liu et al., 2016 Surveys the tumour-biology work: programmed cell death, blockade of autophagy (the cell's recycling process), radiation sensitisation and reversal of drug efflux, alongside the delivery problems limiting translation. Note on coverage: none of the six priority expert platforms listed in this review's search protocol has published anything on this herb. It sits almost entirely outside Western longevity commentary, and the five sources above are the highest-quality overview material available. ## Grokipedia * [Tetrandrine](https://grokipedia.com/page/tetrandrine) Grokipedia's primary entry for the root's main compound — there is none for the herb itself — covering its chemistry, calcium-channel and endosomal targets, Chinese regulatory status in dust-related lung disease, and reported pulmonary toxicity. ## Examine * [Fang Ji](https://examine.com/supplements/fang-ji/) Examine's dedicated monograph for this root, written by Kamal Patel, filed under kidney and urinary health and noting its traditional pairing with *Astragalus membranaceus*; the research breakdown has been archived. ## ConsumerLab ConsumerLab has no article, product review, or quality test covering *Stephania tetrandra* or tetrandrine. The organisation tests supplement categories with substantial consumer sales in the United States, and this root is not sold at that scale outside traditional Chinese herb suppliers. ## Systematic Reviews The reviews and meta-analyses below cover the root, its alkaloids and the principal safety signal attached to the name it is traded under; the clinical trial literature on tetrandrine is generated almost entirely by Chinese hospital and occupational-health groups working in the one country where tetrandrine tablets are a licensed, marketed product, a direct financial and institutional interest in a favourable result. * [History of uses, phytochemistry, pharmacological activities, quality control and toxicity of the root of Stephania tetrandra S. Moore: A review](https://pubmed.ncbi.nlm.nih.gov/32497674/) - Zhang et al., 2020 The most complete systematic survey of the root itself: 48 isolated compounds, 20 traditional indications, quality-control methods, and the liver and kidney toxicity data. * [Drug clinical comprehensive evaluation of tetrandrine in the treatment of pneumoconiosis](https://pubmed.ncbi.nlm.nih.gov/37006149/) - Zhang et al., 2023 Pooled eight randomised trials in pneumoconiosis (dust-related lung disease), reporting gains in breathing capacity and low adverse-reaction rates, and appraising each trial's risk of bias. * [Efficacy and safety of tetrandrine in treatment of rheumatoid arthritis: a meta-analysis](https://pubmed.ncbi.nlm.nih.gov/38650449/) - Xu et al., 2024 Pooled ten randomised trials in rheumatoid arthritis, finding improvement in response rate, inflammatory markers, pain and joint counts, with mild adverse events. * [Thirteen bisbenzylisoquinoline alkaloids in five Chinese medicinal plants: Botany, traditional uses, phytochemistry, pharmacokinetic and toxicity studies](https://pubmed.ncbi.nlm.nih.gov/33166629/) - Zhang et al., 2021 Places tetrandrine among related alkaloids, with predicted absorption, drug-efflux inhibition, and the reactive-metabolite route behind its liver and kidney toxicity. * [Risk assessment of upper tract urothelial carcinoma related to aristolochic acid](https://pubmed.ncbi.nlm.nih.gov/23462915/) - Wu & Wang, 2013 The quantitative counterweight: pooled cancer risk and a dose threshold for kidney failure from the contaminant species that is repeatedly substituted for this root. ## Mechanism of Action The dried root's activity is carried mainly by two closely related bisbenzylisoquinoline alkaloids (a class of large, twin-ringed plant nitrogen compounds), tetrandrine and fangchinoline. Tetrandrine's best-characterised action is blockade of voltage-gated calcium channels of the L-type and T-type — the same protein family targeted by conventional calcium channel blockers — which relaxes arterial smooth muscle and lowers blood pressure, as detailed by [Kwan & Achike](https://pubmed.ncbi.nlm.nih.gov/12466042/). A second, distinct action explains most of the newer interest. Tetrandrine also blocks two-pore channels, calcium channels sitting on endosomes and lysosomes (the cell's internal sorting and digestion compartments). Blocking them stalls the trafficking that some viruses need to enter cells and also stalls the final step of autophagy (the cell's recycling process), as shown by [Sakurai et al.](https://pubmed.ncbi.nlm.nih.gov/25722412/). In lung macrophages (the lung's resident scavenger immune cells) the compound suppresses the NLRP3 inflammasome (a protein complex that converts danger signals into inflammatory output), which [Song et al.](https://pubmed.ncbi.nlm.nih.gov/34417574/) identify as the antifibrotic (scar-limiting) route. It also inhibits NF-κB (a master switch for inflammatory gene expression) and P-glycoprotein (a pump that expels drugs from cells). Mechanistic accounts conflict on whether that scar-limiting effect is primarily macrophage-driven or a direct brake on collagen output by scar-forming cells; both remain live. Pharmacologically, oral absorption is modest and variable, tissue distribution favours lung and liver, reported terminal half-life spans roughly 10 to 20 hours, and metabolism runs through CYP3A4 and CYP3A5 (liver enzymes that clear most drugs), producing a reactive quinone methide intermediate. ## Historical Context & Evolution Han fang ji entered the written record in the Han-dynasty herbals as a treatment for "wind-damp" conditions — swelling, painful joints and scanty urine — and anchors the classical formula Fangji Huangqi Tang, which pairs it with astragalus. Its original use was symptomatic and diuretic (urine-increasing), not systemic. Chemistry redirected it. Tetrandrine was isolated in the first half of the twentieth century, and Chinese pharmacology then found it lowered blood pressure through calcium-entry blockade. From the 1960s onwards Chinese occupational-health institutes tested it against silicosis (the scarring lung disease of dust-exposed workers), and it became the only plant-derived drug licensed anywhere for that indication. Western development took the opposite path. United States National Cancer Institute toxicology on d-tetrandrine in dogs and monkeys, reported by [Gralla et al.](https://pubmed.ncbi.nlm.nih.gov/4213510/), found vascular and lymphoid injury, and the compound was dropped. The 1990s brought the episode that still shapes its reputation. Belgian slimming-clinic patients developed rapidly progressive kidney fibrosis, described by [Vanherweghem et al.](https://pubmed.ncbi.nlm.nih.gov/8094166/); the preparation was later found to contain *Aristolochia fangchi* rather than *Stephania tetrandra*. This was substitution, not an intrinsic property of this root — but it is not fully settled either, since the root's own extracts show liver and kidney toxicity in animals. Renewed Western interest followed the 2015 identification of tetrandrine's endosomal target, and the picture continues to shift in both directions. ## Expected Benefits ### High 🟩 🟩 🟩 #### Slowed Progression of Silica-Induced Lung Fibrosis Tetrandrine slows the scarring that follows inhaled crystalline silica, acting through NLRP3 inflammasome suppression in lung macrophages. The evidence is a meta-analysis of eight randomised trials plus two independent retrospective cohorts in artificial-stone workers and a 2026 randomised trial. This matters to health-optimising adults with any quartz-dust history — engineered-stone fabrication, home renovation, stone carving, sandblasting — for whom no other disease-modifying option exists. All trials come from China, most were unblinded and small, and the institutions running them market the drug. **Magnitude:** A [meta-analysis of eight randomised trials](https://pubmed.ncbi.nlm.nih.gov/37006149/) found added tetrandrine raised forced expiratory volume in one second by 0.13 L (95% confidence interval 0.06–0.20 — the range within which the true value most likely falls) and the ratio of that volume to forced vital capacity by 4.48 percentage points; at 12 months, [49.1% of a treated cohort improved](https://pubmed.ncbi.nlm.nih.gov/40684152/) on imaging versus 0% of untreated controls, among whom 84.6% progressed. ### Medium 🟩 🟩 #### Reduced Rheumatoid Arthritis Disease Activity Tetrandrine reduces joint pain, swelling and morning stiffness in rheumatoid arthritis, plausibly through the same NF-κB and inflammasome suppression. A meta-analysis of ten randomised trials found consistent gains in response rate, pain score, tender and swollen joint counts and inflammatory markers, but no significant change in rheumatoid factor or composite disease-activity score — the two outcomes least open to unblinded reporting bias. All trials were small, Chinese, and used tetrandrine added to conventional therapy rather than alone, so the independent contribution is uncertain. **Magnitude:** [Pooled odds ratio 3.27](https://pubmed.ncbi.nlm.nih.gov/38650449/) (95% confidence interval 2.01–5.37) for overall treatment response across ten randomised trials (an odds ratio is the multiple by which the odds of an outcome differ between groups); standardised mean differences (effect sizes in standard-deviation units) of 0.64 for pain, 1.16 for tender joints and 1.09 for morning stiffness, with adverse events in 20% (95% confidence interval 12–27%). ### Low 🟩 #### Blood Pressure Reduction Tetrandrine blocks L-type and T-type calcium channels and inhibits calcium-dependent output of aldosterone (the salt-retaining hormone) from the adrenal gland, a dual route to lower arterial pressure. Human data are confined to small, old Chinese trials without modern methodology. **Magnitude:** Direction is consistently downward, largest in salt-loaded and kidney-artery-narrowing animal models and at doses producing plasma levels near those needed for calcium-entry blockade; [a review of the cardiovascular pharmacology](https://pubmed.ncbi.nlm.nih.gov/12466042/) reports no pooled millimetre-of-mercury figure from a controlled human trial. #### Chemosensitization in Drug-Resistant Cancer Tetrandrine inhibits P-glycoprotein, the efflux pump that expels chemotherapy from resistant tumour cells, raising intracellular drug concentrations. One multicentre trial in refractory leukaemia supports this; direct antitumour effects remain cell-line work. **Magnitude:** In [38 patients with refractory or relapsed acute myeloid leukaemia](https://pubmed.ncbi.nlm.nih.gov/16219352/), tetrandrine added to daunorubicin, etoposide and cytarabine produced complete remission in 16 (42%) and partial remission in 9, with drug accumulation up a median 88%. ### Speculative 🟨 #### Broad-Spectrum Antiviral Activity Two-pore channel blockade halts endosomal trafficking that several enveloped viruses need. Basis is cell culture, mouse survival data for Ebola virus, and tissue-exposure modelling for the pandemic coronavirus; no human trial reports an outcome. #### Kidney Protection in Diabetes ⚠️ Conflicted Rodent work shows reduced albumin leakage through an antioxidant defence pathway, yet the same root's extracts injure kidneys in other animal models. Basis is mechanistic only; the two animal literatures point opposite ways. #### Suppression of Neuroinflammation Tetrandrine dampens NF-κB-driven activation of microglia (the brain's resident immune cells) in cell culture. Basis is mechanistic alone, with no animal cognitive endpoint and no human data of any kind. ## Benefit-Modifying Factors * **CYP3A5 expressor status:** The gene encoding a liver enzyme that both clears tetrandrine and converts it to a reactive intermediate. Expressors, common in East African and East Asian ancestry, clear the parent compound faster and may reach lower active concentrations at a fixed dose. * **Baseline lung function and imaging stage:** Cohorts show the largest imaging and breathing gains in earlier-stage disease with preserved carbon monoxide transfer; advanced honeycomb-pattern scarring responds little, so baseline testing predicts who benefits. * **Baseline inflammatory markers:** Trials reporting the biggest joint-symptom gains enrolled participants with raised C-reactive protein and erythrocyte sedimentation rate; those already at low inflammatory baseline have less measurable room to improve. * **Sex-based differences:** No trial has reported outcomes split by sex. Women carry higher rheumatoid arthritis rates and generally lower drug clearance, so an equal dose may deliver a larger exposure, but this is inference, not data. * **Pre-existing hepatic function:** Because absorbed drug is heavily processed by the liver before reaching the bloodstream, reduced liver function raises exposure and may amplify effect at a standard dose — while narrowing the margin before toxicity. * **Age at the older end of the range:** Adults over 65 have lower hepatic blood flow and reduced enzyme capacity, raising exposure per dose; they also carry the longest cumulative dust exposure, so absolute benefit may be larger. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Aristolochic Acid Exposure Through Species Substitution The gravest hazard is not the root itself but what is sold as it. *Aristolochia fangchi* (guang fang ji) has been repeatedly substituted for *Stephania tetrandra* (han fang ji) in trade, and it contains aristolochic acid, a potent kidney toxin and a mutagen (an agent that damages DNA) leaving a distinctive genetic signature. The Belgian slimming-clinic outbreak produced rapidly progressive interstitial kidney fibrosis and, years later, cancers of the upper urinary tract. Damage is irreversible and dose-cumulative. **Magnitude:** [Pooled odds ratio 5.97](https://pubmed.ncbi.nlm.nih.gov/23462915/) (95% confidence interval 2.78–12.84) for upper urinary tract cancer among aristolochic acid-exposed people, with a benchmark dose lower confidence limit (the lowest exposure statistically consistent with the observed harm) of 0.42 g cumulative exposure for end-stage kidney disease. ### Medium 🟥 🟥 #### Liver Enzyme Elevation CYP3A4 and CYP3A5 convert tetrandrine into a reactive quinone methide that depletes glutathione (the liver's principal detoxifying molecule). Liver function abnormalities were one of two adverse reactions recorded in the 12-month artificial-stone silicosis cohort, graded mild and reversible on withdrawal. Cell work confirms that forcing CYP3A5 expression raises reactive oxygen species (unstable oxygen molecules that damage cell components), lowers glutathione and increases cell death. **Magnitude:** Direction is a dose- and duration-dependent rise in transaminases (liver enzymes released when liver cells are injured), appearing during multi-month continuous courses rather than short exposure; the [treated cohort of 53 patients](https://pubmed.ncbi.nlm.nih.gov/40684152/) reports the signal without an incidence figure, and no trial supplies a pooled rate. #### Facial and Skin Hyperpigmentation Darkening of facial skin is the most visible and most consistently reported adverse effect of extended tetrandrine courses, recorded alongside liver abnormality in the artificial-stone silicosis cohort. The mechanism is not established; stimulation of melanocytes (pigment-producing skin cells) and light-triggered pigment change have both been proposed. It is cosmetic rather than dangerous and fades slowly after courses end, though it can persist for months. **Magnitude:** Direction is progressive darkening with cumulative dose, described in patients on [180 mg daily across 12 months](https://pubmed.ncbi.nlm.nih.gov/40684152/) of cyclic dosing and deepening with sun exposure; the published cohorts report the effect without a proportion affected. #### Gastrointestinal Intolerance Nausea, appetite loss and abdominal discomfort are the routine dose-limiting complaints across the rheumatoid arthritis and pneumoconiosis (dust-related lung disease) trial literature. The mechanism is likely local mucosal irritation from an alkaloid taken three times daily, since the effect tracks dosing rather than plasma level. It typically eases when doses are taken with food or the daily total is split more finely. **Magnitude:** Adverse events of any type affected [20% of tetrandrine-treated participants](https://pubmed.ncbi.nlm.nih.gov/38650449/) (95% confidence interval 12–27%) across ten randomised rheumatoid arthritis trials, all graded mild; the pooled figure is not broken out by organ system. ### Low 🟥 #### Dose-Related Alveolar Lung Injury ⚠️ Conflicted At high injected doses tetrandrine damages the very organ it is used to treat, through the same CYP3A-generated reactive metabolite that injures liver cells. Blocking that enzyme protects the animals, tying injury to the metabolite rather than the parent compound. Human oral courses have not reproduced it. **Magnitude:** A single injected dose of [150 mg/kg in mice](https://pubmed.ncbi.nlm.nih.gov/21992520/) caused bleeding into the air sacs and a more than three-fold rise in lactate dehydrogenase (an enzyme released by dying cells) in lung washings; human lung cell survival fell about 60% at 40 µM. #### Hypotension and Dizziness Calcium channel blockade lowers arterial pressure, so hypotension (abnormally low blood pressure) and light-headedness on standing are predictable. Trial reports describe both as mild and dose-related. They are most likely in individuals whose resting pressure is already low, and they resolve within a day of stopping. **Magnitude:** Direction is downward and dose-proportional, most noticeable within hours of a dose and in people on other blood-pressure-lowering agents; [the cardiovascular literature](https://pubmed.ncbi.nlm.nih.gov/12466042/) reports no incidence figure for symptomatic hypotension in humans. #### Raised Blood Levels of Co-Administered Drugs Inhibiting P-glycoprotein and CYP3A raises concentrations of drugs cleared by those routes. A previously safe dose of a narrow-margin medicine can become toxic without any change in that medicine's prescription. The effect is pharmacological and predictable rather than idiosyncratic, and reverses when the herb is stopped. **Magnitude:** Tetrandrine-containing plasma raised daunorubicin accumulation in resistant cells by a [median 88%](https://pubmed.ncbi.nlm.nih.gov/16219352/) relative to pre-treatment plasma, and potentiates berberine's glucose-lowering effect in animals through the same pump. ### Speculative 🟨 #### Reproductive and Developmental Toxicity Bisbenzylisoquinoline alkaloids cross membranes readily and disturb calcium-dependent cell division. Basis is isolated animal reports and class-level reasoning; no controlled reproductive toxicology or human pregnancy data exist for this root. ## Risk-Modifying Factors * **CYP3A5 expressor genotype:** Carriers of the functional allele generate more of the reactive quinone methide. Transgenic cells expressing this enzyme show higher oxidative stress, lower glutathione and greater cell death than controls at identical tetrandrine exposure. * **ABCB1 transporter variants:** Polymorphisms in the gene for P-glycoprotein alter both tetrandrine handling and the size of its interaction with co-administered pump substrates, widening or narrowing the interaction risk unpredictably. * **Baseline transaminases and kidney filtration:** Anyone starting with alanine aminotransferase above the functional ceiling, or estimated glomerular filtration rate under 60 mL/min/1.73 m², has less reserve before drug-related change becomes clinically meaningful. * **Sex-based differences:** No safety data are reported by sex. Women show higher rates of drug-induced liver injury generally and were the entire affected population in the Belgian kidney-disease outbreak, though that reflected the clinic's clientele. * **Pre-existing liver or kidney disease:** Impaired clearance raises exposure to both parent compound and reactive metabolite; prior aristolochic acid exposure adds an independent, permanent risk of urinary-tract lining cancer that any further "fang ji" product compounds. * **Age at the older end of the range:** Declining hepatic mass, enzyme capacity and glomerular filtration after 65 raise exposure per dose, while multiple concurrent medicines multiply the chance of a P-glycoprotein or CYP3A interaction. ## Key Interactions & Contraindications * **Calcium channel blockers (amlodipine, nifedipine, verapamil, diltiazem):** Caution — additive blockade risks symptomatic hypotension and reflex tachycardia (a compensating rise in heart rate). Published protocols separate initiation by two weeks and track seated and standing pressure before any dose increase. * **Other antihypertensives (lisinopril, losartan, hydrochlorothiazide, metoprolol):** Caution — additive pressure lowering. Clinical practice reduces the antihypertensive dose rather than the herb when pressure falls below target, with weekly monitoring during the first month. * **CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice):** Caution — raise tetrandrine exposure. Paradoxically these also block formation of the toxic metabolite, so the net effect is unpredictable, and the usual course is avoidance rather than an attempt to balance them. * **CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort):** Caution — reduce tetrandrine levels and may shift metabolism toward reactive intermediates. Concurrent use is generally avoided; no dose adjustment has been validated. * **Narrow-margin P-glycoprotein substrates (digoxin, cyclosporine, tacrolimus, dabigatran, apixaban):** Absolute contraindication without specialist supervision — raised levels risk digoxin toxicity, nephrotoxic immunosuppressant peaks, or major bleeding. Requires drug-level monitoring if unavoidable. * **Cancer chemotherapy (daunorubicin, etoposide, doxorubicin, paclitaxel):** Caution — the same efflux inhibition that reverses resistance also raises marrow and cardiac toxicity. Only under oncology supervision with dose adjustment. * **Over-the-counter loperamide and cimetidine:** Caution — loperamide relies on P-glycoprotein exclusion from the brain, so inhibition risks central opioid effects; cimetidine adds CYP inhibition. A different antidiarrhoeal or acid suppressant is the usual substitution. * **Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen):** Monitor — combined with an alkaloid causing gastric irritation and possible liver enzyme rise, the shared mucosal and hepatic burden increases. Dosing with food and a capped duration are the usual mitigations. * **Supplement interactions (berberine, curcumin, quercetin, piperine, milk thistle):** Caution — all inhibit P-glycoprotein or CYP3A to some degree; berberine's glucose-lowering effect is measurably potentiated by tetrandrine in animals. Separation by at least four hours is the usual mitigation. * **Additive blood-pressure-lowering supplements (magnesium, potassium, hawthorn, garlic extract, beetroot nitrate, taurine):** Monitor — each lowers arterial pressure independently, and stacking them with a calcium channel blocker produces the standing dizziness most users report. Reducing one before another is added is the standard mitigation. * **Other interventions (sauna, hot yoga, prolonged fasting, blood donation):** Caution — all reduce circulating volume or vascular tone and compound the hypotensive effect. Deliberate rehydration and a four-hour gap from any dose are the usual precautions. **Populations who should avoid Stephania tetrandra:** * Pregnancy and lactation, at any dose, given absent reproductive toxicology and confirmed placental transfer of related alkaloids * Documented or suspected prior aristolochic acid exposure, or any history of upper urinary tract urothelial carcinoma (cancer of the urinary tract lining) * Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate below 30 mL/min/1.73 m²) * Active liver disease, Child-Pugh Class B or C cirrhosis (a liver-failure severity grade), or transaminases above three times the upper reference limit * Baseline systolic blood pressure below 100 mmHg, or symptomatic orthostatic hypotension (dizziness or faintness on standing) * Anyone taking digoxin, tacrolimus, cyclosporine or a direct oral anticoagulant without specialist drug-level monitoring * Adults under 18, for whom no dosing or safety data exist ## Risk Mitigation Strategies * **Certified species identity before any use:** A certificate of analysis naming *Stephania tetrandra* by botanical authentication, with aristolochic acid below the limit of quantification, is the baseline safeguard against the substitution that caused irreversible kidney fibrosis and urinary tract cancer. * **Baseline and scheduled liver panel:** Alanine aminotransferase, aspartate aminotransferase and bilirubin are checked before starting, at 4 weeks, then every 3 months, with cessation above three times the upper reference limit, pre-empting reactive-metabolite liver injury. * **Cyclic rather than continuous dosing:** The clinical pattern is 6 dosing days followed by 1 rest day, in 3-month cycles with a break between cycles. It limits the cumulative exposure that drives pigmentation and enzyme elevation. * **Low starting dose with slow titration:** Protocols begin at 60 mg once daily for one week, advancing to twice then three times daily only if tolerated. This surfaces hypotension, dizziness and gastrointestinal intolerance before full exposure. * **Interaction audit before initiation:** A review of every prescription, over-the-counter drug and supplement for P-glycoprotein or CYP3A handling, with unavoidable ones separated by four hours, prevents the toxic level rises that inhibition produces. * **Kidney surveillance after prior fang ji exposure:** Annual filtration rate, urine albumin-to-creatinine ratio and urine cytology (a microscopic check for abnormal shed cells). Aristolochic acid-related tumours appear years later, so detection depends on scheduled surveillance rather than symptoms. * **Daily sun protection during courses:** Broad-spectrum facial sunscreen and shade-seeking through each dosing cycle. This limits the facial hyperpigmentation that is the most commonly reported cosmetic adverse effect of prolonged use. * **Blood pressure log during titration:** Seated and standing readings each morning for the first four weeks. This catches the additive hypotension that arises when the calcium-blocking action stacks with existing antihypertensives or supplements. ## Therapeutic Protocol * **Isolated alkaloid protocol:** The dominant clinical approach uses tetrandrine tablets at 60 mg three times daily, taken for 6 consecutive days with a 1-day break, in 3-month cycles — the schedule used by Shanghai Pulmonary Hospital's pneumoconiosis department. * **Whole-root decoction protocol:** The traditional alternative uses 5–10 g of dried sliced root daily, decocted, usually within the classical astragalus pairing recorded in Zhang Zhongjing's Han-dynasty formulary rather than as a single herb. * **Choosing between them:** Neither is established as superior. The isolated alkaloid gives dose certainty and carries all the trial evidence; the decoction delivers fangchinoline and flavonoids alongside it, with far greater batch variability. * **Best time of day:** Doses are taken with morning, midday and evening meals. Food blunts the gastric irritation that limits tolerance, and the evening dose is often taken earliest to reduce overnight orthostatic symptoms. * **Half-life and dosing frequency:** Reported terminal half-life spans roughly 10–20 hours with extensive lung and liver accumulation, which would permit less frequent dosing; every clinical protocol nonetheless splits the daily total into three, for tolerability rather than kinetics. * **Single versus split dosing:** Split dosing is standard. Consolidating 180 mg into one administration raises peak concentration, and peak-driven effects — dizziness, nausea and reactive-metabolite formation — are the practical limits on this compound. * **Genetic polymorphisms:** CYP3A5 expressor status is the relevant variant, altering both clearance and reactive-metabolite formation. No pharmacogenetic dosing algorithm exists; expressors are simply the group in whom liver monitoring matters most. * **Sex-based differences:** No trial reports dosing or response by sex, and no protocol adjusts for it. Given generally lower body mass and hepatic clearance in women, starting at the lower end of the range is the only defensible inference. * **Age-related considerations:** Adults over 65 are conventionally started at 60 mg once or twice daily rather than three times, reflecting reduced hepatic blood flow, more concurrent medicines, and greater susceptibility to orthostatic falls. * **Baseline biomarkers:** Baseline liver enzymes, estimated glomerular filtration rate, seated blood pressure and — where dust exposure is the indication — spirometry (breathing-capacity testing) with carbon monoxide transfer, set both the dosing ceiling and the yardstick for response. * **Pre-existing conditions:** Impaired liver or kidney function, low resting blood pressure and established heart failure all argue for the lower end of the range or against use entirely, since each narrows the margin before predictable effects become harms. ## Discontinuation & Cycling * **Course-based, not lifelong:** Every clinical protocol runs in defined 3-month cycles rather than indefinitely. Cumulative exposure drives pigmentation and liver enzyme change, so open-ended daily use has no evidential support at all. * **No documented withdrawal syndrome:** Stopping produces no rebound, dependence or discontinuation reaction in any trial or cohort. Blood pressure returns toward baseline over days as calcium channel blockade resolves. * **Tapering generally unnecessary:** Abrupt cessation is standard practice. The exception is anyone whose antihypertensive regimen was reduced to accommodate the herb, where stopping without restoring that dose risks a pressure rebound. * **Cycling is built into the protocol:** The 6-days-on, 1-day-off pattern within 3-month cycles exists to limit toxicity, not to preserve efficacy. No tolerance or loss of response over time has been described. * **Reversibility of adverse effects:** Liver enzyme elevations normalise after withdrawal and facial pigmentation fades over months. Aristolochic acid damage, by contrast, does not reverse, which is why species verification precedes any cycling decision. ## Sourcing and Quality * **Botanical authentication is the decisive test:** An authenticated lot carries a certificate naming *Stephania tetrandra*, verified by microscopy, chromatographic fingerprint or DNA barcoding. Hyperspectral imaging reliably separates it from *Aristolochia fangchi*, but only a supplier that runs a test can report one. * **Aristolochic acid screening below quantification limit:** A complete certificate reports aristolochic acid I and II tested and not detected. The United States Food and Drug Administration has warned against aristolochic acid-containing botanicals since 2001, yet substituted material still circulates. * **Alkaloid standardisation:** The Chinese Pharmacopoeia sets a minimum combined tetrandrine and fangchinoline content for the crude root. Products that do not state assayed alkaloid content give no basis for reproducing any published dose. * **Third-party testing beyond identity:** A complete independent laboratory certificate covers heavy metals, pesticide residues and microbial limits, since this is an imported root crop and none of those contaminants is addressed by botanical identification alone. * **Reputable suppliers:** Established traditional Chinese herb houses that publish per-lot certificates — Nuherbs, Plum Flower (Mayway) and Spring Wind Herbs among them — are the practical route for raw or granulated root in Western markets. * **Pharmaceutical tablets are not exportable:** Tetrandrine tablets are a licensed Chinese prescription medicine with no equivalent approval elsewhere. Products marketed abroad as "tetrandrine" are unregulated extracts, and their stated alkaloid content is frequently unverified. ## Practical Considerations * **Time to effect:** Joint symptom change appears within 4–8 weeks in the arthritis trials. Lung imaging and function change is far slower, with cohort improvements measured at 3 months and consolidating between 6 and 12 months of continuous cycling. * **Common pitfall — the name collision:** Han fang ji and guang fang ji are distinct plants sold under near-identical Chinese names. Ordering by common name rather than verified botanical species is the single most consequential error available here. * **Common pitfall — treating it as a gentle herb:** Its principal action is calcium channel blockade, pharmacologically equivalent to a prescription antihypertensive. Users who stack it with other pressure-lowering agents or skip liver monitoring are misjudging its potency. * **Common pitfall — indefinite daily use:** The protocols are cyclic for toxicological reasons. Continuous dosing on the assumption that more is better is precisely the pattern that produces pigmentation and enzyme elevation. * **Regulatory status:** No approval exists outside China, where tetrandrine tablets are licensed for pneumoconiosis. Elsewhere the root is sold as a dietary or herbal ingredient with no efficacy review, and the isolated alkaloid has no legal medicinal status. * **Cost and payer incentives:** Raw root costs a fraction of licensed antifibrotics such as pirfenidone and nintedanib. Chinese payers therefore have a structural incentive to favour it, Western payers and manufacturers to favour the patented drugs — a bias touching guidelines and funding. ## Interaction with Foundational Habits * **Sleep:** Indirect and mild. No sedative or stimulant effect is described, and no trial reports sleep disturbance. The practical point runs the other way: take the evening dose with the evening meal rather than at bedtime, since blood pressure falls further during sleep and added hypotension causes dizziness on rising overnight. * **Nutrition:** Direct and clinically relevant. Grapefruit and Seville orange inhibit CYP3A4 and are excluded during courses, as is St John's wort, which induces it. Every dose is taken with food to blunt gastric irritation. Adequate protein and fluid support the liver's disposal of the reactive metabolite that drives liver and lung toxicity. * **Exercise:** Potentiating in the hypotensive direction. Calcium channel blockade blunts the reflex vascular tone that maintains pressure after exertion, so post-workout light-headedness is the common complaint. Separating dosing from hard sessions by two hours, and extending cool-downs, addresses it. No effect on strength or hypertrophy adaptation has been reported. * **Stress management:** Indirect. Tetrandrine inhibits calcium-dependent aldosterone output from the adrenal cortex, so it intersects the stress-hormone axis pharmacologically rather than behaviourally. Practices that lower sympathetic tone — breathwork, meditation, sauna — are additive with its pressure-lowering action and can require dose reduction when adopted concurrently. ## Monitoring Protocol & Defining Success Before starting, a baseline panel establishes both the safety floor and the yardstick for response: liver enzymes and bilirubin, estimated glomerular filtration rate with urine albumin-to-creatinine ratio, seated and standing blood pressure, and high-sensitivity C-reactive protein. Where dust exposure is the reason for use, spirometry with carbon monoxide transfer and a high-resolution chest scan are added, since imaging is the outcome the cohort evidence actually measures. Anyone with prior fang ji exposure of uncertain species adds urine cytology. Ongoing monitoring follows the dosing cycles: liver panel and blood pressure at 4 weeks, then every 3 months while dosing continues; kidney function and albumin excretion every 6 months; lung function and imaging at 6 and 12 months. Success means measured stability or gain on the tracked outcome with liver enzymes unchanged, not symptom impression alone. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Alanine aminotransferase | 10–26 U/L (women), 10–33 U/L (men) | Earliest signal of reactive-metabolite liver injury | Conventional labs flag only above ~40 U/L; a doubling within the "normal" range is the real signal. Fast 8 hours; avoid hard exercise 48 hours prior | | Aspartate aminotransferase | 10–26 U/L | Confirms a liver-cell pattern alongside alanine aminotransferase | Conventional labs flag only above ~40 U/L. Rises with muscle damage too, so pair with creatine kinase (a muscle enzyme) before attributing a rise to the herb | | Total bilirubin | 0.3–1.0 mg/dL | Detects impaired processing and bile-duct involvement | Interpret against Gilbert syndrome, which raises unconjugated bilirubin harmlessly in roughly 5% of people | | Gamma-glutamyl transferase | Under 25 U/L (women), under 35 U/L (men) | Cross-checks liver signal and reflects glutathione turnover | Conventional labs allow up to ~40 U/L (women) and ~60 U/L (men). Most sensitive marker of the glutathione depletion this compound causes; best paired with alanine aminotransferase | | Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Detects the kidney injury pattern seen with substituted material | Conventional practice calls anything above 60 mL/min/1.73 m² normal. Creatinine-based estimates overstate function in low-muscle-mass individuals; pair with cystatin C | | Cystatin C | 0.6–1.0 mg/L | Muscle-independent confirmation of filtration | Unaffected by protein intake or training status, so it separates true decline from creatinine artefact | | Urine albumin-to-creatinine ratio | Under 10 mg/g | Detects glomerular leak before filtration rate falls | Conventional practice flags only above 30 mg/g. First-morning void; a single raised result needs confirmation, since exercise and fever transiently raise it | | High-sensitivity C-reactive protein | Under 1.0 mg/L | Tracks the inflammatory outcome the joint trials measured | Conventional cardiovascular risk cut-off is 3.0 mg/L. Repeat only when free of infection; values above 10 mg/L reflect acute illness, not chronic status | | Erythrocyte sedimentation rate | Under 15 mm/h (women), under 10 mm/h (men) | Second inflammatory marker used across the arthritis trials | Conventional ceilings are roughly twice as high (about 30 mm/h in women, 20 mm/h in men). Rises with age and anaemia independently of disease; interpret alongside high-sensitivity C-reactive protein | | Seated blood pressure | 110–125 / 70–80 mmHg | Quantifies the calcium channel blocking effect | Take seated after 5 minutes rest, then standing at 1 and 3 minutes to catch orthostatic drop | | Forced vital capacity and forced expiratory volume in one second | Above 80% of predicted | Primary efficacy outcome where dust exposure is the indication | Same laboratory and same device each time; a 5% change is within measurement noise | | Carbon monoxide transfer factor | Above 80% of predicted | Detects gas-exchange loss earlier than airflow measures | Correct for haemoglobin; falls with anaemia independently of lung disease | | Urine cytology | No atypical urothelial cells | Surveillance where prior aristolochic acid exposure is possible | Only relevant for that group; tumours appear years after exposure, so cadence matters more than any single result | Qualitative markers worth tracking alongside the laboratory panel: * Breathlessness on a fixed effort — the same staircase or gradient, timed and rated weekly * Morning joint stiffness duration in minutes, recorded on waking * Facial skin tone compared against a fixed monthly photograph in consistent light * Light-headedness on standing, logged by frequency rather than severity * Appetite and post-dose nausea, which flag the need to redistribute the daily total * Exercise recovery and resting heart rate trend, as an early indicator of excessive pressure lowering ## Emerging Research * **Connective tissue disease lung involvement:** [NCT07319598](https://clinicaltrials.gov/study/NCT07319598), a recruiting post-approval trial at Peking University Third Hospital, tests tetrandrine tablets in 100 participants with connective tissue disease-associated interstitial lung disease (scarring inflammation of lung tissue), with change in forced vital capacity as the primary endpoint — the first test of the scar-limiting claim outside dust exposure. * **Rheumatoid arthritis confirmation:** [NCT05245448](https://clinicaltrials.gov/study/NCT05245448) at Peking University People's Hospital is registered for 240 participants with the American College of Rheumatology 20% response as its primary endpoint. Its registry status is listed as unknown, and its result would be the first adequately powered test of the joint findings pooled by [Xu et al.](https://pubmed.ncbi.nlm.nih.gov/38650449/), 2024. * **Radiation-induced lung injury prevention:** A randomised controlled trial protocol published by [Liu et al.](https://pubmed.ncbi.nlm.nih.gov/42582976/), 2026, tests tetrandrine injection against radiation-induced lung injury in locally advanced oesophageal squamous cell carcinoma, extending the scar-limiting hypothesis to treatment-caused rather than occupational lung damage. * **Combination with hydrogen inhalation:** [Xiao et al.](https://pubmed.ncbi.nlm.nih.gov/42250702/), 2026, randomised 116 stage II silicosis patients to tetrandrine alone or with hydrogen inhalation, reporting better carbon monoxide transfer and lower interleukin-6 (an inflammatory signalling protein) in the combination arm. It is the most recent randomised evidence and again comes from Chinese occupational-health institutions. * **Antiviral repurposing, unresolved:** [NCT04308317](https://clinicaltrials.gov/study/NCT04308317) registered 60 participants for tetrandrine in COVID-19 and its status remains unknown; a second trial, [NCT05697029](https://clinicaltrials.gov/study/NCT05697029), was withdrawn without enrolling. Tissue-exposure modelling by [Liu et al.](https://pubmed.ncbi.nlm.nih.gov/36699286/), 2023, suggests achievable lung concentrations, but no human outcome exists. * **Kidney protection, both directions:** A 2025 review by [Wang et al.](https://pubmed.ncbi.nlm.nih.gov/41031161/) argues the root protects the diabetic kidney through several pathways, while the dose-response work of [Wu & Wang](https://pubmed.ncbi.nlm.nih.gov/23462915/), 2013, quantifies how the substituted species destroys it. Which literature applies depends entirely on species verification. * **Toxicology that could weaken the case:** The CYP3A5 bioactivation work of [Tian et al.](https://pubmed.ncbi.nlm.nih.gov/26302866/), 2016, implies a genetically defined subgroup at higher risk of liver and lung injury. If confirmed in people, it would narrow the population for whom the benefit-risk balance holds. * **Delivery routes under development:** Inhaled and nanoparticle formulations are being tested to concentrate the compound in lung tissue while avoiding conversion to the reactive metabolite in the liver. Success would change the toxicity profile substantially; all such work remains preclinical, and none has entered registered human trials. ## Conclusion *Stephania tetrandra* is a traditional Chinese root whose main compound behaves less like a gentle botanical and more like a mild prescription drug. It slows the entry of calcium into cells, quietens the inflammatory machinery of lung immune cells, and interferes with a pump that cells use to expel drugs. Its strongest human evidence sits in one narrow place: slowing the scarring lung disease caused by inhaled stone dust, where combined randomised trials and repeated groups of hospital patients show measurable gains in breathing capacity and on imaging. Joint symptom relief in rheumatoid arthritis follows, on weaker support from studies in which everyone involved knew who was being treated. Everything else — blood pressure, cancer, antiviral action, kidney protection — rests on small old studies, single trials or animal work. The main hazards are a slow rise in liver enzymes, visible darkening of facial skin, stomach upset, and interactions that can push other medicines to toxic levels. Overwhelmingly the largest hazard is not the root at all but a different plant sold under a nearly identical Chinese name, which causes permanent kidney destruction and urinary tract cancer. Confidence in the benefits is limited by their source: almost every trial comes from the one country where this compound is a licensed, marketed product, and the institutions running the trials have a stake in the outcome. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**